Now on ScienceBlogs: Charles Darwin February 12, 1809 - April 19, 1882

ScienceBlogs Book Club: Inside the Outbreaks

Terra Sigillata

musings on medicines from the Earth

Profile

Small profile avatar.jpg Abel Pharmboy is the nom de plume of David J Kroll, a US state university educator and cancer researcher who holds a PhD in Pharmacology and Therapeutics and BS in Toxicology. He writes on natural product drugs and dietary supplements, issues of under-represented groups in the STEMM disciplines, science and medical journalism, the science and culture of North Carolina, Florida, and Colorado, making and listening to music and, with the help of his colleague, Erleichda, wine appreciation.

"Why Terra Sigillata?" will tell you more about the origin of the blog name.

Please read the DISCLAIMER for details on the blog's intended audience, advertising and comment policy, and how not to use the information presented herein.

For the record, this is a personal blog and any content or opinions expressed are solely the author's and do not reflect those of his university employer or funding agencies. He does get a bit ornery from time to time.

Recent Posts

Recent Comments

Search This Blog

Archives



 Subscribe in a reader

Add to Google Reader or Homepage

Subscribe in NewsGator Online

Subscribe in Bloglines

http://www.wikio.com


OpenLab2006.png Openlab 2007

Social Media Challenge!

« The new NHS sexual health hub: Could you imagine this happening in the US? | Main | The University of Texas M.D. Anderson Cancer Center takes legal action against Evolv water »

Sir John Crofton, TB combination therapy pioneer - a long and admirable life

Category: HistoryInfectious diseasesMedicinePharmacologyThe Awesome Power of Natural ProductsThe Garden State
Posted on: November 20, 2009 7:40 AM, by Abel Pharmboy

Sir John Crofton.jpgDenise Gellene in the New York Times is reporting this morning that Scottish physician, Sir John Crofton, passed away on 3 November at age 97.

Crofton is best known for implementing a combination drug regimen to treat tuberculosis, the insidious lung infection with Mycobacterium tuberculosis which decimated the US early last century and still kills 2 million a year worldwide. The concept of using drug combinations to increase individual drug potency and slow the emergence of resistance is now a mainstay of therapeutic approaches for cancer, HIV, and other infectious diseases.

Gellene reports that Crofton first investigated streptomycin for TB shortly after the drug's discovery and isolation at Rutgers by Selman Waksman and his then-graduate student, Albert Schatz. Waksman was sole winner of the 1952 Nobel Prize in Physiology or Medicine, with the oversight of Schatz ranked by Scientific American among the top 10 Nobel snubs.

Crofton's original 1950 letter to the British Medical Journal on use of intermittent doses of streptomycin can be seen in this PDF.

Incidentally, the revered German physician, Robert Koch, was awarded the 1905 Nobel Prize in Physiology or Medicine for the discovery of M. tuberculosis. His medical microbiology criteria, known as Koch's Postulates, became the rubric for establishing causation of an infectious agent.

Streptomycin was in short supply after World War II and Crofton had the idea to use subtherapeutic amounts of it together with another drug, 4-aminosalicylic acid (or para-amino, of course, which led to its abbreviation, PAS). In 1951-52, Crofton added isoniazid to the regimen, a compound synthesized first in 1912 but later recognized for activity against the mycobacterium.
Gellene writes:

The third drug was the charm. Through careful monitoring, he devised a regimen that called for starting patients on all three drugs and then stopping streptomycin, which can cause hearing loss, after several months. For more than a decade, until it was replaced by a cocktail of newer and more powerful drugs, Sir John's three-drug regimen was the standard treatment for tuberculosis.

"The treatment principles he developed are the ones we are using today," said Dr. Mario C. Raviglione, director of the World Health Organization's Stop TB department. "They are the model for cancer and for H.I.V. His legacy is quite significant."

Sir John was knighted in 1977, the year he retired from the University of Edinburgh. In the mid-1990s, as an adviser to W.H.O., he helped write the organization's tuberculosis treatment guidelines.

A more detailed and colorful (colourful, in this case) biography of Sir John Crofton by Tam Dalyell appeared on 5 November in the UK Independent.

Share on Facebook
Share on StumbleUpon
Share on Facebook
Find more posts in: Medicine & Health

TrackBacks

TrackBack URL for this entry: http://scienceblogs.com/mt/pings/125144

Comments

1

The same principle is being used in the treatment of leprosy (Dapsone, Rifampicin and clofazimin). I think credit should also be due to him for the elimination of leprosy

Posted by: Girma Teumelissan | November 20, 2009 10:13 AM

2

"Streptomycin was in short supply after World War II..."

That could have been alleviated with a little homeopathy. Crofton could have saved a lot of time... and fewer lives for that matter.

Posted by: Chemgeek | November 20, 2009 1:23 PM

ScienceBlogs

Search ScienceBlogs:

Go to:

Advertisement
Follow ScienceBlogs on Twitter

© 2006-2011 ScienceBlogs LLC. ScienceBlogs is a registered trademark of ScienceBlogs LLC. All rights reserved.